Two new cancer drugs were recommended for approval, and one had its marketing authorization withdrawn at the October meeting of the European Medicines Agency’s advisory panel.
International Approvals
Two new cancer drugs were recommended for approval, and one had its marketing authorization withdrawn at the October meeting of the European Medicines Agency’s advisory panel.
International Approvals
